ARTICLE | Financial News
Abingworth closes BioVentures VII fund at $315M
July 9, 2018 11:35 PM UTC
Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe.
Abingworth's therapeutic interests for BioVentures VII include next-generation cell therapies, antivirals and anti-infectives, Managing Partner Kurt von Emster told BioCentury...
BCIQ Company Profiles